Mylan N.V. (NASDAQ:MYL) Rating Reiterated by Cowen and Company
Mylan N.V. (NASDAQ:MYL)‘s stock had its “hold” rating reiterated by stock analysts at Cowen and Company in a research report issued to clients and investors on Thursday. They presently have a $43.00 price objective on the stock. Cowen and Company’s price target would indicate a potential upside of 30.62% from the stock’s current price.
A number of other brokerages have also commented on MYL. Royal Bank Of Canada decreased their price objective on Mylan N.V. from $39.00 to $36.00 and set a “sector perform” rating on the stock in a report on Thursday, May 11th. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $40.00 price objective on shares of Mylan N.V. in a report on Wednesday, May 31st. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, May 25th. BidaskClub raised Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Barclays PLC raised Mylan N.V. from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $47.00 to $50.00 in a report on Monday, May 22nd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $50.92.
Shares of Mylan N.V. (MYL) traded down 5.13% on Thursday, reaching $32.92. The company had a trading volume of 12,669,007 shares. Mylan N.V. has a 52-week low of $32.77 and a 52-week high of $50.40. The firm has a market capitalization of $17.64 billion, a price-to-earnings ratio of 32.89 and a beta of 1.27. The company’s 50-day moving average price is $38.42 and its 200-day moving average price is $39.28.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, May 10th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.01. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The firm had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same period in the prior year, the firm posted $0.76 EPS. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. On average, analysts predict that Mylan N.V. will post $5.16 earnings per share for the current year.
In related news, insider Anthony Mauro sold 10,000 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider now directly owns 140,653 shares in the company, valued at approximately $5,626,120. The sale was disclosed in a filing with the SEC, which is available through this link. Also, President Rajiv Malik sold 25,000 shares of the company’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $40.00, for a total value of $1,000,000.00. Following the sale, the president now owns 799,855 shares of the company’s stock, valued at $31,994,200. The disclosure for this sale can be found here. 0.69% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in MYL. Quadrature Capital Ltd acquired a new stake in shares of Mylan N.V. during the fourth quarter valued at $707,000. Chevy Chase Trust Holdings Inc. increased its stake in shares of Mylan N.V. by 3.1% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 397,825 shares of the company’s stock valued at $15,511,000 after buying an additional 11,931 shares in the last quarter. New England Research & Management Inc. increased its stake in shares of Mylan N.V. by 3.0% in the first quarter. New England Research & Management Inc. now owns 8,450 shares of the company’s stock valued at $329,000 after buying an additional 250 shares in the last quarter. Raymond James Trust N.A. increased its stake in shares of Mylan N.V. by 33.8% in the first quarter. Raymond James Trust N.A. now owns 10,215 shares of the company’s stock valued at $398,000 after buying an additional 2,583 shares in the last quarter. Finally, Legacy Private Trust Co. acquired a new stake in shares of Mylan N.V. during the first quarter valued at $202,000. Institutional investors and hedge funds own 69.86% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.